XBiotech Inc. (NASDAQ:XBIT) traded down 2.7% during mid-day trading on Monday . The company traded as low as $14.45 and last traded at $14.54, with a volume of 108,155 shares traded. The stock had previously closed at $14.95.

A number of equities research analysts recently issued reports on the company. Noble Financial reiterated a “buy” rating and issued a $30.00 price objective (up previously from $24.00) on shares of XBiotech in a research report on Tuesday, June 28th. Zacks Investment Research upgraded XBiotech from a “hold” rating to a “buy” rating and set a $15.00 price objective on the stock in a research report on Tuesday, May 24th.

The stock’s market cap is $478.46 million. The company’s 50-day moving average price is $17.21 and its 200-day moving average price is $11.84.

In related news, Director W Thorpe Mckenzie bought 20,000 shares of the business’s stock in a transaction on Thursday, May 26th. The stock was acquired at an average price of $13.96 per share, with a total value of $279,200.00. Following the transaction, the director now owns 3,898,600 shares in the company, valued at approximately $54,424,456. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

XBiotech Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. The Company primarily focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.